SynFold uses generative AI to design miniprotein therapeutics against undruggable oncology targets — starting with triple-negative breast cancer, the most aggressive and treatment-resistant subtype.
Our dual computational-experimental pipeline combines generative protein design with rapid in vitro validation — purpose-built for oncology targets that have resisted every small molecule approach.
Our team combines world-class expertise in AI protein design, structural biology, oncology, and drug development — operating at the intersection of computation and the clinic.
We are selectively engaging with investors and strategic partners who share our conviction that AI-designed miniproteins are the next generation of precision oncology therapeutics.